STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront Biotherapeutics (LKFT) repurchases 95,670 shares in July 2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics reported that, under its share repurchase program announced on June 9, 2026, it bought back 95,670 ordinary shares between July 20 and July 24, 2026 via a discretionary mandate to an independent financial intermediary across multiple European trading venues.

The shares were repurchased at an average price of €25.41, for an aggregate consideration of €2,431,442.30, with individual transaction prices ranging from €24.56 to €26.40. As of market close on July 24, 2026, Lakefront held 606,719 of its own ordinary shares.

Positive

  • None.

Negative

  • None.

Filing Explained

As a Form 6-K interim report, this filing incorporates the attached repurchase disclosure into Lakefront’s specified Form S-8 registration statements; its additional effect is on the filing record, not on the buyback mechanics already disclosed.

Shares repurchased 95,670 shares Ordinary shares repurchased between July 20 and July 24, 2026
Average repurchase price €25.41 Average price paid per share over the July 20–24, 2026 period
Total repurchase amount €2,431,442.30 Aggregate consideration for 95,670 shares repurchased
Lowest repurchase price €24.56 Lowest price paid per share during the reported transactions
Highest repurchase price €26.40 Highest price paid per share during the reported transactions
Treasury shares held 606,719 shares Own ordinary shares held as of market close on July 24, 2026
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
discretionary mandate financial
"repurchased 95,670 Lakefront shares via a discretionary mandate to an independent"
independent financial intermediary financial
"via a discretionary mandate to an independent financial intermediary, as follows"
regulated information regulatory
"Mechelen, Belgium; July 28, 2026, 22.01 CET; regulated information"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did Lakefront Biotherapeutics (LKFT) disclose in its July 28, 2026 update?
Lakefront Biotherapeutics disclosed that it repurchased 95,670 ordinary shares between July 20 and July 24, 2026 under its share repurchase program announced on June 9, 2026, using a discretionary mandate to an independent financial intermediary.

How many Lakefront Biotherapeutics (LKFT) shares were repurchased and at what average price?
Lakefront repurchased 95,670 shares at an average price of €25.41 per share. These transactions were executed across several European trading venues during the period from July 20 to July 24, 2026 under the company’s ongoing repurchase program.

What total amount did Lakefront Biotherapeutics (LKFT) spend on the July 20–24, 2026 share repurchases?
Lakefront spent a total of €2,431,442.30 to repurchase 95,670 shares. During this period, the purchase prices ranged from €24.56 to €26.40 per share, reflecting individual trades across multiple European trading venues.

How many treasury shares does Lakefront Biotherapeutics (LKFT) hold after these repurchases?
As of market close on July 24, 2026, Lakefront held 606,719 of its own ordinary shares. This figure reflects the cumulative impact of the July 20–24, 2026 repurchases conducted under the company’s ongoing share repurchase program.

Under what framework were Lakefront Biotherapeutics (LKFT) shares repurchased in July 2026?
The shares were repurchased within the framework of Lakefront’s repurchase program announced on June 9, 2026. Transactions were carried out via a discretionary mandate granted to an independent financial intermediary on various European trading venues.

What price range did Lakefront Biotherapeutics (LKFT) pay for its repurchased shares?
During the July 20–24, 2026 period, Lakefront paid between €24.56 and €26.40 per share. These minimum and maximum prices reflect the lowest and highest transaction prices across all venues used for the repurchases.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On July 28, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated July 28, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: July 28, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; July 28, 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 20, 2026 and July 24, 2026, it has repurchased 95,670 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€)
20/07/2026 XAMS 17,936 26.05 467,150.29 25.62 26.40
20/07/2026 CEUX 3,372 25.79 86,979.73 25.70 26.14
20/07/2026 AQEU 101 25.72 2,597.72 25.72 25.72
20/07/2026 TQEX 74 26.22 1,940.28 26.22 26.22
21/07/2026 XAMS 14,022 25.59 358,820.18 25.34 25.80
21/07/2026 CEUX 1,506 25.57 38,513.84 25.52 25.66
21/07/2026 AQEU 227 25.53 5,795.01 25.52 25.70
21/07/2026 TQEX 506 25.56 12,931.79 25.52 25.58
22/07/2026 XAMS 15,385 25.61 394,028.31 25.48 25.72
22/07/2026 CEUX 1,245 25.63 31,907.36 25.62 25.68
22/07/2026 AQEU 490 25.62 12,553.80 25.62 25.62
22/07/2026 TQEX 185 25.68 4,750.13 25.62 25.68
23/07/2026 XAMS 17,120 25.13 430,292.37 24.70 25.62
23/07/2026 CEUX 2,945 24.81 73,071.34 24.74 25.12
23/07/2026 AQEU 61 24.78 1,511.58 24.78 24.78
23/07/2026 TQEX 61 24.78 1,511.58 24.78 24.78
24/07/2026 XAMS 17,407 24.81 431,940.78 24.56 25.00
24/07/2026 CEUX 1,729 24.77 42,830.62 24.60 24.98
24/07/2026 AQEU 1,159 24.91 28,875.91 24.62 24.96
24/07/2026 TQEX 139 24.75 3,439.68 24.62 24.92
Total   95,670 25.41 2,431,442.30 24.56 26.40

As of market close on July 24, 2026, Lakefront holds 606,719 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases